Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OCTOVA
- 20 Nov 2019 Recruitment completion is expected on 31 Dec 2019, according to ISRCTN: Current Controlled Trials record.
- 20 Nov 2019 Status changed from active, no longer recruiting to recruiting.
- 27 Sep 2018 Planned number of patients changed from 132 to 138.